Theravance Biopharma is a South San Francisco biopharmaceutical company built around a focused respiratory franchise. Its flagship product, YUPELRI (revefenacin), is the first and only once-daily nebulized long-acting muscarinic antagonist approved in the U.S. for COPD maintenance, commercialized with partner Viatris. Spun out of Innoviva in 2014 and trading on Nasdaq as TBPH, the company combines a profitable marketed product with high-value royalty assets - including a now-monetized stake in GSK's TRELEGY - and runs a lean, capital-disciplined model rather than chasing scale.
Rick Winningham is the CEO of Theravance Biopharma, a biopharmaceutical company focused on organ-selective medicines for serious diseases including COPD, rare neurological conditions, and inflammatory diseases. With over 40 years in the pharmaceutical industry - including 13 years as CEO of Innoviva and 15 years at Bristol-Myers Squibb - Winningham has built a career defined by transformative drug development, strategic company leadership, and a widely recognized commitment to mentoring the next generation of biopharma executives, particularly women in leadership. He was named the 2026 HBA Honorable Mentor by the Healthcare Businesswomen's Association.